Sign in

You're signed outSign in or to get full access.

SB

Solid Biosciences Inc. (SLDB)·Q3 2025 Earnings Summary

Executive Summary

  • Solid Biosciences delivered a data-rich Q3 update highlighted by positive interim INSPIRE DUCHENNE readouts (robust microdystrophin expression, biomarker correlations, and early cardiac signals) while pushing its FDA meeting to H1 2026 to assemble a more comprehensive package; cash runway remains into H1 2027 .
  • EPS missed S&P Global consensus as R&D spending accelerated on SGT-003 manufacturing, regulatory, and clinical activity; GAAP net loss per share was $(0.48) vs consensus $(0.44)*, with R&D up to $38.9M (+$11.5M YoY) primarily for SGT-003 .
  • Execution advanced across the pipeline: first sites activated and screening for the ex‑US Phase 3 IMPACT DUCHENNE and the FA Phase 1b FALCON; ARTEMIS (CPVT) site activation expected Q4 2025; AAV‑SLB101 agreements expanded to >30 .
  • Post-quarter, SGT‑003 was granted the UK ILAP Innovation Passport, offering an end-to-end accelerated access pathway with MHRA/NHS/HTA engagement—potentially a medium-term market access catalyst in the UK .
  • Near-term stock narrative likely driven by: strength/consistency of biomarker and cardiac signals in INSPIRE , the regulatory timing shift to H1 2026 , and UK ILAP designation .

What Went Well and What Went Wrong

  • What Went Well

    • Positive INSPIRE DUCHENNE interim data: mean Day 90 microdystrophin 58% (WB/MS), 51% positive fibers (IF); strong correlations with beta‑sarcoglycan and nNOS (r=0.95) and with CK reductions (to Day 180, r as low as −0.78) .
    • Early cardiac signals: mean LVEF trended into normal ranges by Day 180 (N=8) and mean serum cTnI reduced 31% at Day 90 and 70% at Day 360 (N=3) .
    • Management tone: “clear and cascading effect” and conviction SGT-003 can translate molecular impact into outcomes; CMO emphasized steroid‑only prophylaxis and potential cardiac differentiation .

  • What Went Wrong

    • EPS missed consensus due to higher operating spend; GAAP net loss per share $(0.48) vs S&P Global consensus $(0.44)*; total operating expenses rose to $48.1M vs $35.2M YoY .
    • Regulatory timing pushed: FDA meeting moved from Q4 2025 to H1 2026 to provide fuller dataset, external comparator, and initiate PPQ runs—extending the US regulatory path .
    • One treatment-related SAE (Grade 3 immune‑mediated myositis) occurred; responded to steroids with recommendation to continue dosing; thrombocytopenia signals seen early were ameliorated in later patients .

Financial Results

P&L Trends and EPS vs Estimates

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Revenues ($USD)— — — —
R&D Expense ($USD Millions)$27.3 $30.9 $32.4 $38.9
G&A Expense ($USD Millions)$7.9 $9.1 $9.3 $9.2
Total Operating Expenses ($USD Millions)$35.2 $40.1 $41.7 $48.1
GAAP Net Loss ($USD Millions)$(32.7) $(39.3) $(39.5) $(45.8)
GAAP EPS (basic/diluted)$(0.79) $(0.59) $(0.42) $(0.48)
Q3 2025 Actual vs S&P Global ConsensusEPS ($)Revenue ($)
Actual$(0.48) —
Consensus Mean$(0.4407)*$0.0*
Surprise−$0.0393 (miss)In line (pre‑revenue)

Estimates marked with * are values retrieved from S&P Global.

Balance Sheet / Liquidity

MetricQ1 2025Q2 2025Q3 2025
Cash, Cash Equivalents & AFS Securities ($USD Millions)$306.9 $268.1 $236.1
Cash Runway (Company view)Into H1 2027 Into H1 2027 Into H1 2027

Development KPIs (INSPIRE and Platform)

KPIQ1 2025Q2 2025Q3 2025
Participants dosed (INSPIRE)Ongoing; targeting ~20 by YE25 15 dosed as of Aug 12 23 dosed as of Oct 31; 30 by early 2026 planned
Clinical sites active (INSPIRE)8 sites 10 sites 15 sites
Day 90 microdystrophin (mean)Initial 3 patients positive (early interim) Initial 3 showed robust expression (recap) 58% (WB), 58% (MS), 51% positive fibers (IF) (N=10)
Cardiac signalsEncouraging cardiac biomarkers noted in early update —LVEF trend to normal at Day 180 (N=8); cTnI −31% (D90), −70% (D360, N=3)
AAV‑SLB101 agreements19 partners >25 agreements/licenses >30 agreements/licenses

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
FDA meeting to discuss SGT‑003 registrational pathwaysTimingQ4 2025 H1 2026 Pushed
IMPACT DUCHENNE (ex‑US Phase 3)Start/statusInitiate in Q4 2025 First site activated; screening underway (Oct 2025) Achieved/Accelerated
SGT‑212 (FA) FALCON Phase 1bStart/statusInitiate in Q4 2025 First site activated; screening underway (Oct 2025) Achieved
SGT‑501 (CPVT) ARTEMIS Phase 1bStart/statusInitiate in Q4 2025 First site activation expected Q4 2025 Maintained
AAV‑SLB101 licensing2025>25 agreements >30 agreements Increased
Cash runwayMulti‑yearInto H1 2027 Into H1 2027 Maintained

Earnings Call Themes & Trends

Note: No Q3 2025 earnings call transcript was available in the filings/archive used here; themes are synthesized from company press materials and 8‑K.

TopicPrevious Mentions (Q1 2025)Previous Mentions (Q2 2025)Current Period (Q3 2025)Trend
SGT‑003 clinical efficacy signalsEarly interim data in 3 pts showed robust expression and biomarker improvements Reiterated strong initial biopsies; SGT‑003 well tolerated; no TE SAEs 10‑pt Day 90 dataset with 58% mean expression (WB/MS), 51% positive fibers; strong DAPC correlations; CK/LDH/AST/eMHC improvements Strengthening dataset
Cardiac differentiation“Encouraging cardiac biomarkers” in early update —LVEF trend to normal at D180; cTnI reductions at D90/D360 More evidence
Regulatory timing (FDA)Plan to meet later in 2025 Expect to meet Q4 2025 Meeting moved to H1 2026 to expand dataset, external comparator, PPQ prep Later timeline
Ex‑US Phase 3 (IMPACT)—Plan to initiate in Q4 2025 First site activated; screening ongoing Progressed
FA (SGT‑212)IND cleared; start 2H25 Start Q4 2025 First site activated; screening ongoing Progressed
CPVT (SGT‑501)IND‑enabling tox completed; IND planned 1H25 IND cleared; Fast Track; start Q4 2025 First site activation expected Q4 2025 On plan
Platform/capsid out‑licensing19 partners >25 agreements/licenses >30 agreements/licenses Expanding
Market access/UK——UK ILAP Innovation Passport for SGT‑003 (Nov 6) New enabler

Management Commentary

  • CEO Bo Cumbo: “We are observing a clear and cascading effect in the human body, suggesting a coordinated, systemic response to treatment… [these] interim findings reinforce our conviction in SGT‑003’s potential to translate molecular impact into meaningful clinical outcomes.”
  • CMO Gabriel Brooks, M.D.: “SGT‑003 has been generally well tolerated with a minimally burdensome, prophylactic immunomodulatory regimen consisting of steroids alone… early data suggests stabilization and improvement in cardiac function.”
  • CEO on timing: moving the FDA meeting to H1 2026 enables a fuller dataset, external comparator work, PPQ manufacturing readiness, and initiation of IMPACT DUCHENNE before the meeting .

Q&A Highlights

Not available; the company furnished results via 8‑K and press release, and no Q3 2025 earnings call transcript was located in the company document archive used here .

Estimates Context

  • Q3 2025 GAAP EPS was $(0.48) vs S&P Global consensus $(0.4407)*; miss driven by higher R&D primarily for SGT‑003 manufacturing, regulatory, and clinical costs and higher personnel costs .
  • Revenue consensus was $0.0* (pre‑revenue biotech), consistent with the company’s lack of reported product revenue .

Estimates marked with * are values retrieved from S&P Global.

Key Takeaways for Investors

  • SGT‑003 profile is maturing with consistent microdystrophin expression across orthogonal assays, strong DAPC correlations, and early cardiac signals (LVEF/cTnI), supporting potential functional benefit and differentiation vs peers .
  • US regulatory discussion moved to H1 2026 to maximize the strength of the package (more patients, external comparator, PPQ readiness), extending the timeline but potentially de‑risking review quality .
  • Execution momentum: ex‑US Phase 3 IMPACT DUCHENNE and FA Phase 1b FALCON have initiated site activation/screening; CPVT Phase 1b site activation remains slated for Q4 2025 .
  • UK ILAP Innovation Passport could accelerate UK interactions and access planning, adding an ex‑US market access angle to the story .
  • Operating spend will remain elevated given rapid clinical scale‑up and manufacturing prep; expect estimates to adjust for higher near‑term R&D and updated US regulatory timing .
  • Liquidity is solid with $236.1M and runway into H1 2027; runway underpins completion of key 2026 milestones (FDA meeting, PPQ, continued dosing) .
  • Risk watch: immune‑mediated myositis SAE (resolved) and evolving regulatory expectations; continued safety, cardiac, and functional data maturation will be pivotal for valuation inflection .